Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Immunoprecipitation

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Learning to fear novel stimuli by observing others in the social affordance framework.

Neuroscience and biobehavioral reviews·2025

Same author

Classroom aerosol dispersion modeling: experimental assessment of a low-cost flow simulation tool.

Environmental science. Processes & impacts·2023

Same author

Cerebellar Clustering and Functional Connectivity During Pain Processing.

Cerebellum (London, England)·2015

Same author

Distribution of the neural antigen BSP-2 in the cerebellum during development.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2014

Same author

Raising polyclonal antibodies using nitrocellulose-bound antigen.

Methods in molecular biology (Clifton, N.J.)·2012

Same author

European quality system for tissue banking.

Transplantation proceedings·2009

Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026

Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 16, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Raising polyclonal antibodies using nitrocellulose-bound antigen.

M Diano¹, A L Bivic, M Hirn

¹Biohgie de la Differenciation Cellulaire, Faculte des Sciences de Luminy, Marseilles, France.

Methods in Molecular Biology (Clifton, N.J.)

|November 15, 2012

Summary

This summary is machine-generated.

Obtaining specific antibodies against low-abundance or insoluble proteins is challenging due to limited protein availability and purity. This study addresses the difficulties in antibody production for minor and difficult-to-purify protein targets.

More Related Videos

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Published on: August 17, 2015

Generation of Monoclonal Antibodies Against Natural Products

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Related Experiment Videos

Last Updated: May 16, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77

Published on: August 17, 2015

Generation of Monoclonal Antibodies Against Natural Products

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Area of Science:

Biochemistry
Immunology
Protein Chemistry

Background:

Generating specific antibodies against low-abundance proteins in biological fluids is difficult.
Nonsoluble cytoplasmic or membraneous proteins present purification and antibody generation challenges.
Classical purification methods often yield insufficient protein quantities and low purity.

Purpose of the Study:

To investigate the challenges in obtaining highly specific antibodies against minor or nonsoluble proteins.
To identify the key limitations in current protein purification and antibody production techniques.

Main Methods:

Analysis of classical protein purification processes.
Evaluation of protein yield and purity after purification.
Assessment of antibody generation success rates against purified proteins.

Main Results:

Small protein amounts after purification limit antibody development.
Low protein purity further hinders the generation of specific antibodies.
Nonsoluble protein characteristics complicate purification and subsequent antibody production.

Conclusions:

Current purification methods are inadequate for producing sufficient high-purity antigens for antibody generation.
Developing novel strategies is crucial for obtaining specific antibodies against challenging protein targets.